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Rap1 deﬁciency-provoked paracrine
dysfunction impairs immunosuppressive
potency of mesenchymal stem cells in
allograft rejection of heart transplantation
Yue Ding1,2,3, Xiaoting Liang2,4,5, Yuelin Zhang2,6, Li Yi7, Ho Cheung Shum8, Qiulan Chen8, Barbara P. Chan8,
Huimin Fan9, Zhongmin Liu4,9, Vinay Tergaonkar10, Zhongquan Qi3, Hung-fat Tse2 and Qizhou Lian 2,7,11
Abstract
Immunomodulatory activity of mesenchymal stem cells (MSCs) is largely mediated by paracrine factors. Our previous
studies showed that activation of nuclear factor-kappa B (NF-κB) regulates cytokine/growth factor secretion by MSCs.
This study aimed to elucidate the role of Rap1 (repressor/activator protein), a novel modulator involved in the NF-κB
pathway, in regulating the immunomodulatory potency of MSCs in acute allograft rejection of heart transplantation.
The immunosuppressive potency of wild-type MSCs (WT-MSCs) or Rap1-deﬁcient MSCs (Rap1−/−-MSCs) was examined
in mice with acute allograft rejection following heart transplantation. With a combination of immunosuppressant
rapamycin at a dose of 1 mg/kg/d, WT-MSCs notably prolonged the survival of the transplanted heart compared with
Rap1−/−-MSCs. Rap1−/−-MSCs displayed a marked insensitivity to inhibit the mixed lymphocyte reaction (MLR) due to
impaired cytokine production and a signiﬁcantly reduced activity of NF-κB signaling in vitro. Finally, transplantation of
encapsulated WT-MSCs greatly prolonged the survival of the heart allograft compared with encapsulated Rap1−/
−-MSCs. Our results indicate that Rap1 is essential to maintain the immunomodulatory function of MSCs. Deletion of
Rap1 results in impaired immunomodulatory function of MSCs.
Introduction
Mesenchymal stem cells (MSCs) have been used to
regulate the innate and adaptive immune system as a
potential approach to prevent or treat allograft rejection
following kidney transplantation1, hematopoietic stem
cell transplantation2, and in animal models of allogeneic
heart and islet transplantation3,4. Nonetheless, knowledge
of the immunosuppressive capacity of MSCs remains
limited. Bone marrow MSCs fail to prevent graft-versus-
host disease (GVHD) in mice although they suppress
lymphocyte proliferation in vitro5. In clinical trials,
application of MSCs for therapy-resistant GVHD showed
moderate or even worsened efﬁcacy in a subset of
patients6. Recent studies have demonstrated that the
immunosuppressive ability of MSCs is not constitutive
but inducible. Li and colleagues proposed that the degree
of nitric oxide production elicited by proinﬂammatory
cytokines in the surrounding environment inﬂuenced
MSCs to be either potently immunosuppressive or highly
immune enhancing7. Thus, to guarantee a most effective
activation of their immunosuppressive characteristics,
more detailed information about the mechanisms and
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signaling pathways may help to harness MSC as an
immunoregulator.
Although the potential mechanisms underlying MSC-
mediated immunomodulation are not fully understood,
accumulating evidence demonstrates that production of
soluble factors is predominately responsible8. The
nuclear factor-kappa B (NF-κB) family of transcription
factors plays a critical role in coordinating the expression
of a wide variety of inﬂammatory-related genes, includ-
ing cytokines, chemokines, and adhesion molecules, to
regulate immune responses9. It has been documented
that NF-κB activation mediates cytokine/growth factor
secretion by MSCs10. It is thus reasonable to postulate
that intervention with NF-κB to regulate its paracrine
capacity can affect the immunoregulatory effects of
MSCs.
Recently, we performed a genome-wide gain-of-
function screen and unexpectedly identiﬁed a telomeric
protein Rap1 (repressor/activator protein) as an IκB
kinase (IKK) adapter that modulates NF-κB in a dose-
dependent manner11. Rap1-mutant mice showed a
defective NF-κB signaling and reduced the generation of
responding cytokines when stimulated by lipopoly-
saccharides (LPS)11. Whether Rap1 is involved in reg-
ulating the immunomodulatory potential of MSCs has not
been investigated. In this study, we aimed to determine
whether inhibition of Rap1 could affect the immunomo-
dulatory potential of MSCs by regulating the responding
cytokine proﬁling.
Results
Characterization of Rap1−/−-MSCs
First, the genotyping of Rap1 knockout (Rap1−/−) and
wild-type (WT) mice was performed as previously descri-
bed11,12. MSCs isolated from tibias were cultured until
passage 4 to exclude non-adherent hematopoietic cells.
Similar to wild-type MSCs (WT-MSCs), MSC surface
markers were positive for CD105, CD73, CD90, CD44,
Sca1, and not contaminated for CD34 or CD45 positive
hematopoietic cells in Rap1 knockout MSCs (Rap1−/
−-MSCs) (Supplementary Fig. 1A). The multiple differ-
entiation potential for adipogenesis, chondrogenesis, and
osteogenesis was not affected by Rap1 knockout (Supple-
mentary Fig. 1B). Moreover, Rap1 deﬁciency in MSCs did
not affect their proliferation in vitro (Supplementary Fig.
1C). Rap1 expression was negative in Rap1−/−-MSCs and
positive in WT-MSCs, examined by immunostaining
(Fig. 1a) and western blotting (Fig. 1b), respectively. Fur-
thermore, MSCs were successfully labeled with green
ﬂuorescent protein (GFP) by lentiviral infection, conﬁrmed
by immunoﬂuorescence (Fig. 1c).
Rap1 activates NF-κB transcriptional activity in MSCs
The relationship between NF-κB and Rap1 was exam-
ined in vitro. A gene construct pNF-κB-Luc carrying
luciferase as a reporter was used to examine the cellular
activities of the corresponding signaling pathways. This
construct contains a phosphorylated NF-κB (pNF-κB)
enhancer element located upstream of the secreted
Fig. 1 Lentiviral GFP labeling of MSCs. Rap1 expression was negative in Rap1−/−-MSCs but positive in WT-MSCs, examined by immunostaining (a)
and western blotting (b), respectively. c Rap1−/−-MSCs and WT-MSCs were successfully infected with lentiviral GFP, detected by immunostaining. N:
non-signiﬁcance. Scale bar= 200 μM.
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luciferase gene. Binding of transcription factors to the
pNF-κB enhancer element allows luciferase to be
expressed and secreted into the surrounding medium. As
shown in Fig. 2, Rap1−/−-MSCs were transfected with the
indicated plasmids. Groups A and C received reporter
plasmid pNF-κB-Luc, whereas group B received empty
pNF-κB-Luc as controls. The amount of expression
plasmid for Rap1 (Fig. 2a, b) and IκB-dominant negative
(IκB DN) (Fig. 2c) was progressively increased as indicated
from 1 to 5 µL (60 ng of DNA/µL). Compared with empty
controls (Fig. 2b), pNF-κB activation was gradually
enhanced along with an increasing amount of Rap1 pla-
mids (Fig. 2a). In contrast, overexpression of IκB DN
largely abolished Rap1-activated pNF-κB-Luc activity
(Fig. 2c). These results showed that the activity of NF-κB
transcriptional signaling was activated by Rap1.
Impaired immunomodulatory functions of Rap1−/−-MSCs
in allogeneic heart transplantation
To examine whether Rap1 deﬁciency in MSCs leads to
an impaired immunomodulatory potency in vivo, the
recipient C57/B6 mice were treated with Rap1−/−-MSCs/
WT-MSCs combined with rapamycin (RAPA) at a dose of
1 mg/kg/d as described previously4,13. The median survi-
val time (MST) of transplanted hearts treated with a high
dose of rapamycin (H_RAPA) was 18 days (H_RAPA
group, Fig. 3a), compared with 11 days in the low-dose
group (L_RAPA group, Fig. 3a). Infusion of MSCs and a
low dosage of RAPA was synergistic in promoting cardiac
allograft tolerance, especially in the L_RAPA+WT-MSC
group where MST was prolonged to 24.5 days (Fig. 3a),
compared with 14 days in the L_RAPA+ Rap1−/−-MSC
group (Fig. 3a, p < 0.05). We also examined platelet (PLT)
and white blood cell (WBC) counts at 48 h after surgery
because a decrease in these two variables is a primary
toxic side effect of RAPA14. PLT and WBC counts showed
a dose-dependent toxicity during RAPA treatment, and
Rap1−/−-MSCs and WT-MSCs were equally capable of
reversing the downtrend (Fig. 3b). To quantify the survival
rate of transplanted cells, cardiac allografts were digested
at 48 h after transplantation. The result showed that very
few GFP+ cells were detected (Fig. 3c-i&ii).
Combination of rapamycin and WT-MSCs, but not Rap1−/
−-MSCs, more effectively prevents inﬂammation and
induces differential regulation of tolerance-associated
CD4+Foxp3+ regulatory T cells in the cardiac allograft
To evaluate the severity of inﬂammatory inﬁltration
following transplantation, the corresponding ISHLT
(International Society of Heart and Lung Transplantation)
score of the hearts harvested from the different treatment
groups was assessed as previously described15. The myo-
cardium of the grafts from the control group (ISHLT
Grade 4) showed extensive necrosis and inﬁltration of
inﬂammatory cells (Fig. 4a-i&ii). However, the grafts from
the H_RAPA, L_RAPA, and L_RAPA+ Rap1−/−-MSC
groups (ISHLT Grade 3) showed moderate lymphocyte
inﬁltration and tissue damage (Fig. 4a-i&ii). L_RAPA+
WT-MSC group (ISHLT Grade 1) presented the lowest
level of lymphocytic inﬁltration and fewest changes in
myocardial structural integrity among all groups (Fig. 4a-
i&ii). The inﬂammatory monocyte population of the
allograft was analyzed by ﬂow cytometry at 48 h after
transplantation. RAPA reduced the percentage of CD45+
cells in a dose-dependent manner (Fig. 4b-i&ii). Notably,
WT-MSCs were more capable in suppressing CD45+
inﬂammatory cell inﬁltration than Rap1−/−-MSCs
(Fig. 4b-i&ii). Lymphocytes separated from spleens and
Fig. 2 Rap1 activates NF-κB transcriptional activity. a Rap1−/
−-MSCs were transfected with pNF-κB luciferase reporter pNFκB-Luc. b
Transfection of an empty pNF-κB-Luc was set as controls. The
amounts of expression plasmid for Rap1 (a, b) and IκB DN (c) were
progressively increased as indicated from 1 to 5 µL (60 ng of DNA/µL).
RLA was expressed as ﬁreﬂy luciferase activity after it was normalized
to Renilla luciferase activity (n= 3 for each group). *p < 0.05; N: non-
signiﬁcance, IκB DN: IκB-dominant negative, RLA: relative luciferase
activity.
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allograft transplants of recipient mice were analyzed by
FACS (ﬂuorescence-activated cell sorter) at 48 h after
transplantation. Compared with the L_RAPA+ Rap1−/
−-MSC group, the proportion of CD4+FOXP3+ reg-
ulatory T cells (Tregs) was signiﬁcantly increased in the
L_RAPA+WT-MSC group (Fig. 4c). To evaluate the
inﬂammation status systematically, we collected the
serum from cardiac puncture and performed cytokine
proﬁling at 48 h after transplantation. L_RAPA+ Rap1−/
−-MSC and L_RAPA+WT-MSC treatment groups had a
comparable level of anti-inﬂammatory cytokine IL-10
(interleukin 10) and TGF-β (transforming growth factor
β), but proinﬂammatory cytokines IFN-γ (interferon-γ),
TNF-α (tumor necrosis factor α), and IL-6 (interleukin 6)
were signiﬁcantly lower in the L_RAPA+WT-MSC
group than those in the L_RAPA+ Rap1−/−-MSC group
(Fig. 4d). Collectively, the data suggested that WT-MSCs
are superior to Rap1−/−-MSCs in ameliorating lympho-
cyte inﬁltration and inducing immune tolerance.
Reduced potency of Rap1−/−-MSCs to inhibit MLR in vitro
is mainly through impaired cytokine secretion, and not
cell–cell contact
Immunomodulation of MSCs is believed to occur
through MSC-immune cell contacts and/or MSC-
secreted cytokines16. In a coculture setting, in which
cell–cell communication and paracrine effects are
involved, WT-MSCs and Rap1−/−-MSCs displayed a
comparable ability to suppress the mixed lymphocyte
reaction (MLR), and a gradual enhanced inhibition was
observed in line with an increasing proportion of MSCs
(Fig. 5a). We next investigated the role of paracrine effects
in regulating MLR. At ﬁrst, we compared the paracrine
effects between WT-MSCs and Rap1−/−-MSCs, at rest
status, on suppression of MLR. As shown in Fig. 5b-i, c,
poorer concentrations of secreted proteins were observed
in the conditioned medium of Rap1−/−-MSCs
(CM_Rap1−/−-MSCs) compared with that in WT-MSCs
(CM_WT-MSCs) (Fig. 5c, p < 0.05). Although both
Fig. 3 Rap1 deﬁciency in MSCs impairs their ability as immune adjuvants of rapamycin. a Graft survival was shown by Kaplan–Meier method
and compared by log-rank test (n= 16 for each group). #p < 0.05 vs. L_RAPA+ Rap1−/−-MSC group. b WBC and PLT count were measured at 48 h
after transplantation (n= 6 for each group). c Cell engraftment in the transplanted heart was determined by GFP-positive cell sorting (n= 3 for each
group). *p < 0.05; N: non-signiﬁcance, WBC: white blood cell, PLT: platelet.
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Fig. 4 (See legend on next page.)
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CM_Rap1−/−-MSCs and CM_WT-MSCs suppressed
MLR, a much stronger inhibition was observed in
CM_WT-MSCs (Fig. 5d, p < 0.05). Moreover, WT-MSCs
exhibited a superior ability in cytokine secretion com-
pared with Rap1−/−-MSCs, including proinﬂammatory
factors (IFN-γ, TNF-α, and IL-6), and anti-inﬂammatory
factors (IL-10 and TGF-β) (Fig. 5e).
Next, to understand paracrine effects of MSCs, at active
status, on suppression of MLR, the conditioned medium
collected from MLR (CM_MLR) was used as an inducer to
activate Rap1−/−-MSCs and WT-MSCs, as shown in
Fig. 5b-ii. After washing away of CM_MLR stimulation, the
conditioned medium of MSCs was harvested for cytokine
proﬁling and MLR experiment. It showed that, compared to
rest status, CM_MLR treatment effectively increased pro-
tein yield in the conditioned medium of both Rap1−/
−-MSCs andWT-MSCs (Fig. 5c, p < 0.05 vs. non-CM_MLR
treatment) and enhanced their ability to suppress MLR
(Fig. 5d, p < 0.05 vs. non-CM_MLR treatment).
CM_MLR treatment demonstrated its effectiveness in
stimulating immunomodulatory cytokine secretion:
CM_MLR induced Rap1−/−-MSCs (iCM_Rap1−/
−-MSCs) and WT-MSCs (iCM_WT-MSCs) had a higher
abundance of cytokines compared with their untreated
counterparts (Fig. 5c), indicating that the immunomo-
dulatory effects of MSCs are inducible. Importantly,
Rap1−/−-MSCs exhibited a markedly reduced capacity to
respond to CM_MLR stimulation compared with WT-
MSCs, as evidenced by signiﬁcantly decreased cytokine
release, including proinﬂammatory cytokines (IFN-γ,
TNF-α, and IL-6) and anti-inﬂammatory cytokines (IL-10
and TGF-β) (Fig. 5e).
Absence of Rap1 downregulates NF-κB activity in MSCs
We used lipofectin transfection to overexpress Rap1
into Rap1−/−-MSCs, and referred it as Rap1+/+-MSCs.
Western blotting showed that Rap1 expression was suc-
cessfully restored to a level comparable to WT-MSCs in
Rap1+/+-MSCs (Fig. 6a). NF-κB p65 expression level was
lower in Rap1−/−-MSCs compared with WT-MSCs, but
its expression was restored in Rap1+/+-MSCs (Fig. 6a). A
signiﬁcantly higher ratio of pNF-κB p65/NF-κB p65 was
detected in WT-MSCs compared with Rap1−/−-MSCs
following CM_MLR treatment, and the trend was partially
rescued by Rap1 overexpression (Fig. 6a). The activity of
NF-κB was inhibited by NF-κB signaling inhibitor QNZ,
demonstrated by a signiﬁcantly lower ratio of pNF-κB
p65/NF-κB p65, especially in WT-MSCs and Rap1+/
+-MSCs (Fig. 6a). To determine whether downregulated
NF-κB activity resulted in dysfunction of cytokine secre-
tion in MSCs, we tested the secreted level of IFN-γ, TNF-
α, IL-6, and IL-10, which are reported to be largely con-
trolled by NF-κB signaling pathway17–20. Protein levels of
IFN-γ, TNF-α, IL-6, and IL-10 were signiﬁcantly lower in
Rap1−/−-MSCs compared with those in WT-MSCs after
CM_MLR treatment (Fig. 6b). Replenishing Rap1
expression in Rap1−/−-MSCs alleviated secretion of the
above cytokines to a level comparable to WT-MSCs
(Fig. 6b). NF-κB inhibitor QNZ signiﬁcantly reduced the
above cytokine secretion (Fig. 6b). Rap1+/+-MSCs
demonstrated a better capacity in paracrine function
compared to Rap1−/−-MSCs, but not as capable as WT-
MSCs (Fig. 6b). Collectively, the absence of Rap1 impairs
NF-κB activity and results in dysfunction of cytokine
secretion in MSCs.
Transplantation of encapsulated WT-MSCs more effectively
prolongs the survival of the allogeneic heart than Rap1−/
−-MSCs
We have demonstrated that Rap1−/−-MSCs have dis-
tinct cytokine secretion compared to WT-MSCs (Fig. 5e),
and cell engraftment was barely detected in the cardiac
allograft (Fig. 3c), suggesting that the paracrine factors
might act predominantly in regulating allogeneic rejec-
tion. To allow analysis of the secreted factors from MSCs
in the regulation of allograft survival, we used sodium
alginate to encapsulate Rap1−/−-MSCs and WT-MSCs
(Fig. 7a), in which cells are able to survive and release
cytokines dynamically without direct exotic–autologous
contacts21. The encapsulated MSCs were able to survive
in vitro for about 10 days (Fig. 7b). The encapsulated
Rap1−/−-MSCs (E_Rap1−/−-MSCs) or encapsulated WT-
MSCs (E_WT-MSCs) were intraperitoneally infused into
mice that underwent heart transplantation. RAPA was
applied as the dominant immunosuppressant and
E_Rap1−/−-MSCs or E_WT-MSCs functioned as an
immunological adjuvant. In agreement with the outcome
of direct Rap1−/−-MSC/WT-MSC treatment (Fig. 3a), the
(see ﬁgure on previous page)
Fig. 4 Rap1 deﬁciency decreases the immunosuppressive ability of MSCs in vivo. a Representative photographs showing the ISHLT score for
each group (i) and typical H&E staining of grafts (ii) (n= 6 for each group). Scale bar= 100 μM. b Quantiﬁcation of inﬁltrating CD45+
mononucleocyte population in cells isolated from transplanted hearts at 48 h after surgery by FACS analysis (n= 3 for each group). c Proportions of
splenic and allograft transplant CD4+Foxp3+ Treg cells were analyzed by ﬂow cytometry at day 2 post transplantation (n= 3 for each group). d The
concentration of IFN-γ, TNF-α, IL-6, IL-10, and TFG-β in sera from rejected hearts was measured by Flowcytomix (n= 10 for each group). *p < 0.05; **p
< 0.01; ***p < 0.001; N: non-signiﬁcance.
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Fig. 5 Rap1 deﬁciency impairs MSC paracrine action to suppress MLR. a WT-MSCs and Rap1−/−-MSCs showed a signiﬁcant and comparable
capacity to inhibit MLR in a coculture setting (n= 3 for each group). b Schematic diagram showing (i) the rest status of MSC-conditioned medium
collection process and (ii) active status of MSC-conditioned medium collection process. c Differential concentration of secreted protein in the
conditioned medium was determined among different stimulatory conditions (n= 3 for each group). d Conditioned medium from Rap1−/−-MSCs
showed inferior capacity to suppress MLR compared with WT-MSCs (n= 3 for each group). e Cytokine proﬁling showed that Rap1 deﬁciency resulted
in impaired cytokine secretion in MSCs, including proinﬂammatory cytokines (IFN-γ, TNF-α, and IL-6), and anti-inﬂammatory cytokines (IL-10 and TGF-
β). *p < 0.05; **p < 0.01; ***p < 0.001; N: non-signiﬁcance.
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combination of E_WT-MSCs and RAPA treatment
achieved a longer allograft survival than E_Rap1−/
−-MSCs (Fig. 7c), suggesting that the cytokines released
from MSCs are involved in regulating allograft rejection.
Nonetheless, although the tendencies were generally the
same, the effects of encapsulated MSCs were weaker than
direct cell injection, as shown by a relatively shorter sur-
vival time of the allografts (Fig. 3a vs. Fig. 7c).
Discussion
In this study, there were several major ﬁndings (Fig. 8).
First, as an adjunctive therapy to RAPA, Rap1−/−-MSCs
displayed a reduced potency to prolong the allograft
survival compared with WT-MSCs, with more inﬁltration
of inﬂammatory cells, less Tregs, and a higher level of
proinﬂammatory cytokines. Second, paracrine effects
exerted a leading role in MSC-mediated MLR
Fig. 6 Absence of Rap1 downregulates NF-κB activity in MSCs. a Western blotting showed the activity of NF-κB pathway in active status with/
without NF-κB inhibitor QNZ treatment. b Cytokine proﬁling showed that Rap1 deﬁciency downregulated NF-κB-related cytokine secretion in MSCs
(n= 3 for each group). *p < 0.05; **p < 0.01; ***p < 0.001; N: non-signiﬁcance.
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Fig. 7 E_WT-MSCs more effectively extend allograft survival than E_Rap1−/−-MSCs as immune adjuvants of rapamycin. a Morphological
presentation of newly made encapsulated MSCs. b Encapsulated Rap1−/−-MSCs/WT-MSCs after 10 days of culture. c Graft survival was shown by
Kaplan–Meier method and compared by log-rank test (n= 10 for each group). #p < 0.05 vs. L_RAPA+ E_Rap1−/−-MSC group. Scale bar= 200 μM.
Fig. 8 Scheme summarizing the proposed mechanism of action behind Rap1 deletion in MSC-mediated immunomodulation. The absence
of Rap1 reduces the efﬁcacy of MSCs paracrine via inhibiting the NF-κB signal pathway, which decreases the immunosuppressive potency of MSCs.
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suppression. Rap1 deﬁciency in MSCs resulted in a
decreased capacity to inhibit MLR and reduced sensitivity
to produce responsive cytokines which linked to impaired
NF-κB activity. Third, by transplanting encapsulated
MSCs, we demonstrated that although not as efﬁcient as
direct cell transplantation, the bioactive cytokines secre-
ted from MSCs showed a longer allograft survival than
RAPA monotherapy. The absence of Rap1 reduced the
efﬁcacy of MSC secretome in suppressing immune
rejection following heart transplantation.
MSCs are highly heterogeneous and pleiotropic cells
that are highly sensitive to different microenvironments,
especially those containing cytokines. Although the
majority of studies have demonstrated the immunosup-
pressive capacity of MSCs, additional investigations have
shown immunostimulatory properties7. Given their ver-
satility in immune modulation, MSCs have received
considerable attention. A more thorough understanding
of the detailed molecular mechanisms might be helpful
for precise control of MSC behavior in physiological and
pathological environments, and be of practical as well as
fundamental value to biomedical research.
The NF-κB transcription factor family is a pleiotropic
regulator involved in the control of a large number of
normal cellular and organic processes, providing a
mechanism for cells to respond to a wide variety of stimuli
linked to inﬂammation22. Inhibition of NF-κB activation
has been considered a potential therapy for inﬂammatory
diseases. Phosphorylation of IκB proteins by the IκB
kinase (IKK) complex is a crucial step in pathways and
leads to NF-κB activation. It is thus logical to postulate
that inhibition of IKK should have an anti-inﬂammatory
effect by suppressing NF-κB activation. Nonetheless, in
practice, IKK inhibitor treatment enhances proin-
ﬂammatory IL-1β production and neutrophil accumula-
tion that increases the susceptibility to infection23,24,
suggesting that NF-κB also exerts an anti-inﬂammatory
effect. Therefore, the identiﬁcation of critical regulator(s)
that modulate(s) immune tendentiousness in the func-
tioning of the NF-κB signal pathway is of importance.
Using a genome-wide gain-of-function screen, we iden-
tiﬁed Rap1 as a novel IKK adapter that speciﬁcally mod-
ulates NF-κB-dependent transcription in mammals by
enhancing the recruitment of IKKs to the NF-κB
p65 subunit11.
MSCs and the NF-κB pathway have countereffects with
pro- and anti-inﬂammatory properties. This makes the
results of their combination unpredictably complicated.
In a mouse model of myocardial infarction (MI), we
showed that the absence of Rap1 in MSCs reduced the
secretion of proinﬂammatory cytokines and had favorable
protective effects post infarction25. Nonetheless, in the
context of allogeneic heart transplantation which arouses
a violent immune response, Rap1 expression is
irreplaceable for MSCs to execute immune-suppressive
functions. When injected in vivo, Rap1−/−-MSCs are less
efﬁcient in downregulating proinﬂammatory cytokine
concentration in the transplanted allograft compared with
WT-MSCs, but yield comparable capacity to affect anti-
inﬂammatory cytokines. This disrupts the ﬁne balance
between pro- and anti-inﬂammatory mechanisms. In
vitro, deletion of Rap1 in MSCs leads to paracrine insuf-
ﬁciency: both pro- and anti-inﬂammatory cytokines are
downregulated. Our data were partly in accordance with
our previous study in which deletion of Rap1 reduced the
proinﬂammatory factor release by MSCs25, but in the
current study, Rap1 deﬁciency also reduced anti-
inﬂammatory factors. The reduced release of anti-
inﬂammatory cytokines might serve a predominant role
rather than proinﬂammatory cytokines, which tilts the
scale toward a proinﬂammatory state and leads to a
decreased ability to suppress MLR in Rap1−/−-MSCs
compared with WT-MSCs. In addition, we utilized
encapsulation methods to deliver MSCs in vivo that
allowed dynamic cytokine release without direct cell–cell
contact. The effectiveness of paracrine actions in inducing
allograft tolerance is afﬁrmed, although not as evident as
direct cell injection. E_Rap1−/−-MSCs are inferior to
E_WT-MSCs in extending allograft survival, indicating
that the absence of Rap1 reduces the ability of MSCs to
secrete immunosuppressive factors.
The functions of MSCs are not constitutive or ﬁxed, but
rather the result of a cross talk with the microenviron-
ment26. MSCs are able to sense their environment and
secrete biologically active substances responsively27.
Therefore, to harness the therapeutic potential of MSCs,
signaling pathways or speciﬁc genes that hold the
potential to modulate cytokine secretion should be spe-
ciﬁcally sought in different disease models. The absence of
Rap1 in MSCs decreases the NF-κB sensitivity to stress-
induced proinﬂammatory cytokine production and redu-
ces apoptosis, and therefore beneﬁts the therapeutic efﬁ-
cacy in MI25,28. Nonetheless, in the current study, the
deﬁciency of Rap1 in MSCs appeared detrimental in
suppressing cardiac allograft rejection. We understand the
contradictory effects of Rap1 from two aspects. First,
MSCs are exposed to different environments in MI and
heart transplantation. The pathological characteristics of
MI are multistage and intricate, involving edema,
nucleomegaly, acute and chronic inﬂammation, granula-
tion, and ﬁbrotic tissue formation29. On the contrary,
heterotopic heart transplantation mainly arouses an allo-
graft immune response30. As clairvoyant as MSCs, they
might act differently in accordance with the milieu to
which they are exposed. Second, in the MI model, MSCs
were delivered into the myocardium where dystrophy
caused by ischemia seriously hampers cell survival. In the
current study, we injected MSCs into the peritoneum
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where cell survival could be better preserved by forming
aggregates in the peritoneum and producing immunor-
egulatory molecules31,32.
In summary, our study suggests that Rap1 is essential
for MSCs to maintain their immunomodulatory func-
tions. Deletion of Rap1 results in immunomodulatory
impairment of MSCs. How Rap1 regulates the speciﬁcity
of NF-κB signaling pathways for immunomodulatory
functions of MSCs deserves further investigation.
Materials and methods
Animals
BALB/C and C57/B6 mice were purchased from the
laboratory animal unit of the University of Hong Kong.
Rap1−/− and WT mice were kind gifts from the laboratory
of Dr. Vinay Tergaonkar in Singapore. The handling of
the animals and experimental protocols applied in this
study were approved by the Committee on the Use of Live
Animals in Teaching and Research (CULATR, Approval
ID 2817-12) at the University of Hong Kong33.
Isolation and characterization of MSCs
For MSC isolation, tibias and ﬁbulas of Rap1−/− or WT
mice (6–8 weeks) were isolated and ﬂushed using a 29-G
syringe. The MSCs were cultured in complete medium that
comprised DMEM/low glucose (Hyclone, SH30021.02), 15%
FBS (Life Technologies, 16000), 5 ng/mL epidermal growth
factor (PeProTech, AF-100-15), 5 ng/mL ﬁbroblast growth
factor (PeProTech, 100-18B), 0.1mM 2-mercaptoethanol
(Life Technologies, 21985023), Glutamax (Life Technologies,
35050061), NEAA (Life Technologies, 11140050) and
penicillin–streptomycin (Life Technologies, 15140122). The
isolated cells were allowed to expand until passage 4–8, and
then a subset of MSCs was used for characterization as
described below. The others were set aside for transplanta-
tion and in vitro experiments.
MSCs were characterized by surface marker proﬁling and
their ability to differentiate into three germ layers. Cell-
surface antigens for MSCs were analyzed by ﬂow cyto-
metry. We incubated 1.5 × 105 cells with each of the fol-
lowing conjugated antibodies: CD105-PE (eBioscience, 12-
1051-81), CD90.2-PE (eBioscience, 12-0903-82), CD73-PE
(eBioscience, 12-0731-81), CD45-PE (eBioscience, 12-
0451-82), CD44-APC (eBioscience, 17-0441-82), CD34-
APC (eBioscience, 17-0349-42), and Sca1-APC
(eBioscience, 17-5981-82). Nonspeciﬁc ﬂuorescence was
determined by incubation of similar cell aliquots with
isotype-matched antibodies (eBioscience). Data were ana-
lyzed by collecting 30,000 events on a Beckman Coulter
FC500 using CXP Analysis 2.0 software. For differentiation
ability, adipogenesis, chondrogenesis, and osteogenesis of
MSCs was determined using the relevant commercial kit
according to the manufacturer’s instructions (adipogenesis:
Life Technologies, A1007001; chondrogenesis: Life
Technologies, A1007101; and osteogenesis: Life Technol-
ogies, A1007201). Oil red, alcian blue, and alizarin red
staining for adipocytes, chondrocytes, and osteocytes,
respectively, was performed using standard techniques
after differentiation as previously described34.
Cell proliferation assay
Cell proliferation was assayed using CCK-8 kit (CK04,
Dojindo) as per the manufacturer’s protocol. Brieﬂy,
MSCs were plated into a 96-well plate and incubated with
CCK-8 for 2 h at 37 °C. Absorbance was subsequently
measured on a spectrophotometer at 450 nm. Three
independent experiments were performed.
Role of Rap1 in regulating NF-κB activity
Expression plasmid pAG304-Rap1 was constructed by
inserting Rap1 gene containing ﬂanked BamH1 and Xho1
restriction sites into pAG304 vector under the control of
cytomegalovirus (CMV) promoter (Supplementary Fig. 2).
Reporter plasmids pNF-κB-Luc and negative controls were
acquired from BPS Bioscience (San Diego, CA). IκB DN was
described previously35. Rap1−/−-MSCs were grown at 37 °C,
and 2 × 105 cells were seeded onto a 35-mm culture plate a
day before transfection. Cells were transfected using Lipo-
fectamine 2000 (Life Technologies, 11668019) with the
respective constructs as described previously36. Cells were
harvested 48 h after transfection, and the luciferase activity
was determined according to the manufacturer’s instructions.
Murine heart transplantation model
Vascularized heterotopic heart transplantation was
performed from BALB/C donors to C57/B6 mice reci-
pients by anastomosing the vessels of the neck using a
non-suture cuff technique at day 037. Recipient mice
received rapamycin from Day 0 to Day 10 via intragastric
administration unless the cardiac allografts lost contrac-
tion ability. For MSC-treated groups, mice were grouped
to receive intraperitoneal injection of WT-MSCs, Rap1−/
−-MSCs, E_WT-MSCs, or E_Rap1−/−-MSCs at Day 1
(1 × 106/100 μL per mouse). Animals were grouped as
listed in Table 1. Each group contained 16 mice, and graft
condition was observed twice daily. Loss of palpable car-
diac contraction was deﬁned as complete rejection.
WBC and PLT measurement
Blood was harvested from the tail vein using a capillary
tube at 48 h after surgery. The number of WBC and PLT
was counted using a cell counter.
Transplanted cell engraftment in cardiac allograft
For live cell counting, the cardiac allograft was enzy-
matically digested at 48 h after transplantation. Dis-
sociated cells were separated by ﬁltering through a 30-μm
ﬁlter. Most of the cardiomyocytes (>30-μm diameter)
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were discarded and the small cell fraction (<30 μm) was
collected. The number of GFP+ cells was counted using
FACSAria II.
Histological evaluation of rejection
As soon as the cardiac allografts stopped beating, they
were harvested and ﬁxed with 10% PBS–formalin.
Parafﬁn-embedded transventricular tissue sections (5 μm)
were processed for hematoxylin and eosin (H&E) staining.
The rejection score was determined by the extent of
leucocytic inﬁltration and anatomical destruction of
myocytes according to the criteria published by ISHLT38.
Cellular phenotypic expression
Inﬁltrating CD45+ mononucleocyte population in cells
isolated from transplanted hearts was examined by FACS
at 48 h after surgery. For phenotypic analysis of
CD4+Foxp3+ Treg cells, the cardiac allograft and spleen
cells from the recipients were collected at 48 h after
transplantation. CD4+Foxp3+ Treg cells were identiﬁed
using an anti-mouse Foxp3-APC (eBioscience, 88-8118-
40) staining set, along with a CD4-FITC (eBioscience, 11-
0042-85) antibody.
Cytokine proﬁle in vivo
To distinguish the modulatory effects of Rap1−/
−-MSCs/WT-MSCs in a cardiac transplantation model,
mice serum was collected via puncture of the allograft in
different groups at 48 h after surgery. The cytokines were
measured using Flowcytomix (eBioscience, BMS820FFSA)
as per the manufacturer’s instructions.
In vitro MLR assay
To determine whether MSCs regulate the immune
response, Rap1−/−-MSCs or WT-MSCs in gradient
concentrations (2.5 × 104/well; 0.25 × 104/well; and
0.025 × 104/well) were seeded in a 96-well round-bottom
plate and cultured at 37℃ in a humidiﬁed incubator for 4
h to allow cell adherence. BALB/C donor splenocytes
were prepared as stimulator cells following treatment with
mitomycin C (40 μg/mL, Sigma, M0503). C57/
B6 splenocytes were used as responder cells. The stimu-
lator cells (BALB/C splenocytes) were mixed with
responder cells (C57/B6 splenocytes) at a ratio of 1:10
(0.5 × 105: 5 × 105/well) in MLR culture medium
(RPMI1640 supplemented with 10% fetal bovine serum,
1% penicillin, and streptomycin; 200 μL/well), and then
added to the Rap1−/−-MSC/WT-MSC pre-seeded plates.
Since the MSCs were seeded in gradient concentrations
(2.5 × 104/well; 0.25 × 104/well; and 0.025 × 104/well), the
ratio of MSCs (5 × 105/well) to responder cells was 1:20,
1:200, and 1:2000, respectively. The mixture of stimulator
and responder cells was added to non-MSC plates as MLR
controls. Responder cells cultured in a medium without
stimulator cells served as a negative control. There were
triplicate wells for each group. After 72 h of coculture, cell
proliferation was quantiﬁed using a bromodeoxyuridine
(BrdU) kit (Roche Applied Science, 11647229001)
according to the manufacturer’s instructions.
To determine whether the paracrine effects generated
by MSCs inﬂuence the MLR response, a concentrated
conditioned medium collected from Rap1−/−-MSCs/WT-
MSCs was applied to the MLR mixture. The conditioned
medium (CM) was prepared as previously described.7
Brieﬂy, when Rap1−/−-MSCs/WT-MSCs were 90% con-
ﬂuent on a 10-cm plate, the growth medium was aspi-
rated, and the cells were washed three times with PBS
(phosphate buffer solution), followed by the addition of 8
mL of DMEM (Gibco, 11880-036). The CM was collected
after 24 h, and referred to as CM_Rap1−/−-MSCs or
Table 1 Experimental groups
TREATMENT GROUPS
Ctrl H_RAPA L_RAPA L_RAPA + Rap1−/
−-MSCs
L_RAPA + WT-
MSCs
L_RAPA + E_Rap1−/
−-MSCs
L_RAPA + E_WT-
MSCs
Heart
transplantation
+ + + + + + +
RAPA (1 mg/kg/d) − − + + + + +
RAPA (2 mg/kg/d) − + − − − − −
Rap1−/−-MSCs − − − + − − −
WT-MSCs − − − − + − −
E_Rap1−/−-MSCs − − − − − + −
E_WT-MSCs − − − − − − +
RAPA: rapamycin, Rap1−/−-MSCs: Rap1 knockout MSCs, WT-MSCs: wild-type MSCs, E_Rap1−/−-MSCs: encapsulated Rap1−/−-MSCs, E_WT-MSCs: encapsulated WT-MSCs.
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CM_WT-MSCs (Fig. 5b-i). Since MSC secretome may
differ under inﬂammatory conditions compared with the
normal physiological environment, the supernatant of
activated lymphocytes, referred to as CM_MLR, was
prepared by coculturing stimulator cells (BALB/C sple-
nocytes) and responder cells (C57/B6 splenocytes) at a
ratio of 1:10 for 96 h. Then, CM_MLR was added to
Rap1−/−-MSCs/WT-MSCs as an inducer and cultured for
24 h. CM_MLR was aspirated, and the cells were washed
three times with PBS prior to the addition of 8 mL of
DMEM (Gibco, 11880-036). The supernatant was col-
lected after a further 24 h to allow efﬁcient cytokine
release, and referred to as iCM_Rap1−/−-MSCs or
iCM_WT-MSCs. The experimental schematic diagram is
depicted in Fig. 5b-ii. After collection, the CM was cleared
by centrifugation, ﬁltered through a 0.22-μm Millipore
ﬁlter, and then placed into an Amicon Ultra-4 Centrifugal
Filter Unit (Millipore, UFC801024) for puriﬁcation and
concentration according to the manual with a con-
centration factor of 10 before application in the MLR
assay. After 72 h of coculture, cell proliferation was
quantiﬁed by BrdU assay.
Cytokine proﬁling in vitro
CM_WT-MSCs, CM_Rap1−/−-MSCs, iCM_WT-MSCs,
and iCM_Rap1−/−-MSCs were collected, concentrated as
described above, and quantiﬁed by Bradford assay (BIO-
RAD, 5000202). The secreted level of IFN-γ, TNF-α, IL-10,
IL-6, and TGF-β was measured using a bead-based analyte
detection System-Flowcytomix (eBioscience, BMS820FFSA)
according to the manufacturer’s instructions.
Restoring Rap1 expression in Rap1−/−-MSCs
Rap1 overexpressing plasmid was purchased from
TAKARA. Transient transfection was performed using
Lipofectamin 2000 (Thermo Scientiﬁc, 11668019)
according to the manufacturer's instructions. At 48 h after
transfection, Rap1 expression was measured via western
blotting analysis.
QNZ treatment
QNZ was purchased from Sellectchem (S4902). Rap1−/
−-MSCs, Rap1+/+-MSCs, and WT-MSCs were cultured
in T25 until they reached 85–90% conﬂuency, and then
CM_MLR was added as an inducer and cultured for 24 h.
CM_MLR was aspirated, and the cells were washed three
times with PBS prior to the addition of 5 mL of DMEM
(Gibco, 11880-036) and QNZ (11 nM). After 24 h of
incubation, the supernatant was collected and con-
centrated. The secreted level of IFN-γ, TNF-α, IL-6, and
IL-10 was measured using a bead-based analyte detection
System-Flowcytomix (eBioscience, BMS820FFSA),
according to the manufacturer’s instructions. Cells were
harvested and used for western blotting analysis.
Western blotting
Cells were harvested and lysed in RIPA buffer (Sigma,
R0278) supplemented with complete ULTRA tablets
(ROCHE, 5892970001). The protein concentrations were
measured by BCA protein assay kit (Thermo Scientiﬁc
Pierce, 23235). A total amount of 30 μg of protein from
each sample was loaded. Samples were separated by SDS/
PAGE and then transferred to a PVDF membrane.
Membranes were blocked in 5% wt/vol fat-free milk (BIO-
RAD, 170-6404) and then incubated with the following
primary antibodies overnight at 4 °C: Rap1 (Thermo Sci-
entiﬁc, PA5-27588), GAPDH (eBioscience, 14-9523-80),
NF-κB p65 (Abcam, ab32536), and pNF-κB p65 (Abcam,
ab194921). After washing, membranes were incubated
with appropriate HRP-conjugated secondary antibodies at
a 1:1000 dilution. Bands were detected using enhanced
chemiluminescence (GE Healthcare, RPN2232).
Preparation of encapsulated MSCs
For the cell encapsulation experiment, 2.0% (w/w)
sodium alginate (Aladdin Chemistry Co., Ltd., China)
dissolved in distillation–distillation water was prepared as
the precursor solution by magnetic stirring for 1 h. A
volume of 3.0 wt.% calcium chloride (Wing Hing Che-
mical Co., Ltd., Hong Kong) solution was prepared and
added to a collection bath. Afterward, MSCs were mixed
with the precursor solution to form a cell suspension with
a density of 1 × 109 cells/mL.
To achieve cell-encapsulated hydrogel particles with
controlled sizes, we electrosprayed the liquid jet under a
controlled electric ﬁeld. When a high voltage was applied,
the liquid jet was stretched by the electric stress and
assumed a tapered shape. Next, the tapered jet broke up
into uniform alginate droplets that were collected in a
bath of calcium chloride solution. The alginate droplets
were subsequently cross-linked by calcium ions and
formed calcium alginate hydrogel particles.
The number of cells per particle could be manipulated
by varying the density of the cells in the precursor sus-
pension; the size of the particles was in turn controlled by
the magnitude of the electric ﬁeld. In this study, with an
applied electric ﬁeld of 3.2 × 105 V/m, the average dia-
meter of the particles was 206 μm; each particle contained
an average of 4580 cells.
Statistical analysis
All data are presented as the mean ± standard error of
mean (SEM). Allograft survival curves were plotted using
the Kaplan–Meier method, and the difference in allograft
survival among groups was compared using the log-rank
test. A comparison of parameters between two groups was
performed by unpaired Student’s t-test. Comparison of
variables between multiple groups was performed using
one-way ANOVA with the Bonferroni post hoc test.
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Calculations were performed with SPSS 16.0 and p < 0.05
was considered statistically signiﬁcant.
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